A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

ALS

Interventions

BIOLOGICAL

TCD601

Investigational Product

Trial Locations (3)

Skåne University Hospital Malmö, Malmo

Studieenheten Akademiskt Specialistcentrum, Stockholm

Umeå University Hospital, Umeå

All Listed Sponsors

lead

ITB-Med LLC

INDUSTRY

NCT06453668 - A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients | Biotech Hunter | Biotech Hunter